Immunoglobulin News and Research

RSS

Research provides fresh insight into structure of sodium channels

Sodium channels are implicated in many serious conditions such as heart disease, epilepsy and pain, making them an important potential target for drug therapies. Unfortunately, there is still much scientists do not know about the molecules.

18 Apr 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.

21 Mar 2014

Researchers look at health threat to pregnant women with history of Kawasaki disease

In the first study of its type, researchers at the University of California, San Diego School of Medicine have looked at the health threat to pregnant women with a history of Kawasaki disease (KD), concluding that the risks are low with informed management and care.

7 Mar 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies.

26 Feb 2014

Infliximab drug shows promising results in treating children with Kawasaki Disease

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. If not diagnosed or treated in time, it can lead to irreversible heart damage.

25 Feb 2014

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

Marker for inflammatory bowel disease linked to bipolar disorder

Researchers have found evidence that the gastrointestinal tract plays a role in the inflammatory pathology of bipolar disorder, suggesting the need to consider dietary modification and anti-inflammatory treatment for some patients.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Lymphotoxin is a cytokine, or intercellular messenger, and plays an important role in the immunological balance of the gastrointestinal tract. It regulates the immune system of the digestive tract, which is made up of immune cells, immunoglobulins (antibodies) as well as intestinal bacteria.

10 Dec 2013

Autumn-born children prone to asthma

Month of birth closely correlates with the prevalence of bronchial asthma, a major study of Taiwanese children has found.

5 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

The American Academy of Dermatology (Academy) has released new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy red patches of skin.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

Researchers discover powerful mechanism that keeps white blood cells from going rogue

The immune system is a double-edged sword. While its primary role is to fight infections, it can also become overactive, leading to problems like allergies and autoimmune diseases.

13 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Specific antibody patterns predict schizophrenia risk

The presence of antibodies to multiple foods and infectious agents is a risk marker for new-onset schizophrenia, a case-control study suggests.

23 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Immunoglobulin News and Research

Research provides fresh insight into structure of sodium channels

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Researchers look at health threat to pregnant women with history of Kawasaki disease

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Infliximab drug shows promising results in treating children with Kawasaki Disease

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Marker for inflammatory bowel disease linked to bipolar disorder

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Autumn-born children prone to asthma

EMA expands administration options for Hizentra

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Researchers discover powerful mechanism that keeps white blood cells from going rogue

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Specific antibody patterns predict schizophrenia risk

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News